Pasar al contenido principal

ACTIVACION DE LA VIA PPARB/D-GDF15 PARA EL TRATAMIENTO DE LA RESITENCIA A LA INSULINA Y LA DIABETES MELLITUS TIPO 2

PID2021-122116OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns

  • Barroso, Emma
  • Díaz, Marta
  • Reguera, Ana Cristina
  • Peyman, Mona
  • Balsinde, Jesús
  • Jurado-Aguilar, Javier
  • Zhang, Meijian
  • Rostami, Adel
  • Palomer, Xavier
  • Ibáñez, Lourdes
  • Vázquez-Carrera, Manuel
[Background]: The placentas from newborns that are small for gestational age (SGA; birth weight < -2 SD for gestational age) may display multiple pathological characteristics. A key determinant of fetal growth and, therefore, birth weight is placental amino acid transport, which is under the control of the serine/threonine kinase mechanistic target of rapamycin (mTOR). The effects of endoplasmic reticulum (ER) stress on the mTOR pathway and the levels of amino acid transporters are not well established. [Methods]: Placentas from SGA and appropriate for gestational age (AGA) newborns and the human placental BeWo cell line exposed to the ER stressor tunicamycin were used. [Results]: We detected a significant increase in the levels of C/EBP homologous protein (CHOP) in the placentas from SGA newborns compared with those from AGA newborns, while the levels of other ER stress markers were barely affected. In addition, placental mTOR Complex 1 (mTORC1) activity and the levels of the mature form of the amino acid transporter sodium-coupled neutral amino acid transporter 2 (SNAT2) were also reduced in the SGA group. Interestingly, CHOP has been reported to upregulate growth arrest and DNA damage-inducible protein 34 (GADD34), which in turn suppresses mTORC1 activity. The GADD34 inhibitor guanabenz attenuated the increase in CHOP protein levels and the reduction in mTORC1 activity caused by the ER stressor tunicamycin in the human placental cell line BeWo, but it did not recover mature SNAT2 protein levels, which might be reduced as a result of defective glycosylation. [Conclusions]: Collectively, these data reveal that GADD34A activity and glycosylation are key factors controlling mTORC1 signaling and mature SNAT2 levels in trophoblasts, respectively, and might contribute to the SGA condition., This study was partly supported by the grants RTI2018-093999-B-I00 and PID2021-122116OB-I00 (M.V.-C.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

  • Zhang, Meijian
  • Barroso, Emma
  • Ruart, Maria
  • Peña, Lucía
  • Peyman, Mona
  • Aguilar-Recarte, David
  • Montori-Grau, Marta
  • Rada, Patricia
  • Cugat, Clara
  • Montironi, Carla
  • Zarei, Mohammad
  • Jurado-Aguilar, Javier
  • Camins, Antoni
  • Balsinde, Jesús
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached a phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we examined the effects of elafibranor in mice fed a choline-deficient high-fat diet (CD-HFD), a model of metabolic dysfunction-associated steatohepatitis (MASH) that presents obesity and insulin resistance. Our findings revealed that elafibranor treatment ameliorated steatosis, inflammation, and fibrogenesis in the livers of CD-HFD-fed mice. Unexpectedly, elafibranor also increased the levels of the epithelial-mesenchymal transition (EMT)-promoting protein S100A4 via PPARβ/δ activation. The increase in S100A4 protein levels caused by elafibranor was accompanied by changes in the levels of markers associated with the EMT program. The S100A4 induction caused by elafibranor was confirmed in the BRL-3A rat liver cells and a mouse primary hepatocyte culture. Furthermore, elafibranor reduced the levels of ASB2, a protein that promotes S100A4 degradation, while ASB2 overexpression prevented the stimulating effect of elafibranor on S100A4. Collectively, these findings reveal an unexpected hepatic effect of elafibranor on increasing S100A4 and promoting the EMT program., This study was partly supported by the grants RTI2018-093999-B-I00 and PID2021-122116OB-I00 (M.V-C.), PID2021-122766OB-I00 (A.M.V.), and PID2019-105989RB-I00 (J.B.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of Gadd45a Expression in Mice Leads to Cognitive and Synaptic Impairment Associated with Alzheimer’s Disease Hallmarks

  • Griñán-Ferré, Christian
  • Jarne-Ferrer, Júlia
  • Bellver-Sanchis, Aina
  • Ribalta-Vilella, Marta
  • Barroso, Emma
  • Salvador Sánchez, Jesús María
  • Jurado-Aguilar, Javier
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
  • Pallàs, Mercè
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Gadd45 genes have been implicated in survival mechanisms, including apoptosis, autophagy, cell cycle arrest, and DNA repair, which are processes related to aging and life span. Here, we analyzed if the deletion of Gadd45a activates pathways involved in neurodegenerative disorders such as Alzheimer’s Disease (AD). This study used wild-type (WT) and Gadd45a knockout (Gadd45a−/−) mice to evaluate AD progression. Behavioral tests showed that Gadd45a−/− mice presented lower working and spatial memory, pointing out an apparent cognitive impairment compared with WT animals, accompanied by an increase in Tau hyperphosphorylation and the levels of kinases involved in its phosphorylation in the hippocampus. Moreover, Gadd45a−/− animals significantly increased the brain’s pro-inflammatory cytokines and modified autophagy markers. Notably, neurotrophins and the dendritic spine length of the neurons were reduced in Gadd45a−/− mice, which could contribute to the cognitive alterations observed in these animals. Overall, these findings demonstrate that the lack of the Gadd45a gene activates several pathways that exacerbate AD pathology, suggesting that promoting this protein’s expression or function might be a promising therapeutic strategy to slow down AD progression., This research was funded by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) PID2021-122116OB-100 (M.V.-C.), PID2022-139016OA-100 (C.G.-F), and PDC2022-133441-100 (M.P.), Generalitat de Catalunya (2021 SGR 00357). This study was co-financed by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092). A.B-S acknowledges the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021 FISDU 00182). This study was also partly supported by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and CIBER de Enfermedades Neurodegenerativas (CIBERNED) are a Carlos III Health Institute project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress

  • Peyman, Mona
  • Barroso, Emma
  • Turcu, Andreea L.
  • Estrany Jr., Francesc
  • Smith, Dáire
  • Jurado-Aguilar, Javier
  • Rada, Patricia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Valverde, Ángela M.
  • Palomer, Xavier
  • Galdeano, Carles
  • Vázquez, Santiago
  • Vázquez-Carrera, Manuel
Soluble epoxide hydrolase (sEH) is a drug target with the potential for therapeutic utility in the areas of inflammation, neurodegenerative disease, chronic pain, and diabetes, among others. Proteolysis-targeting chimeras (PROTACs) molecules offer new opportunities for targeting sEH, due to its capacity to induce its degradation. Here, we describe that the new ALT-PG2, a PROTAC that degrades sEH protein in the human hepatic Huh-7 cell line, in isolated mouse primary hepatocytes, and in the liver of mice. Remarkably, sEH degradation caused by ALT-PG2 was accompanied by an increase in the phosphorylated levels of AMP-activated protein kinase (AMPK), while phosphorylated extracellular-signal-regulated kinase 1/2 (ERK1/2) was reduced. Consistent with the key role of these kinases on endoplasmic reticulum (ER) stress, ALT-PG2 attenuated the levels of ER stress and inflammatory markers. Overall, the findings of this study indicate that targeting sEH with degraders is a promising pharmacological strategy to promote AMPK activation and to reduce ER stress and inflammation., This study was partly supported by grants RTI2018-093999-B-100 and PID2021-122116OB-I00 (M.V-C.), PID2020-118127RB-I00 (S.V.), PID2021-127693OB-I00 (C.G.) and PID2021-122766OB-I00 (A.M.V.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. CERCA Programme/Generalitat de Catalunya. Partial support was provided by NIH – NIEHS (RIVER Award) R35 ES030443-01, NIH – NIEHS (Superfund Award) P42 ES004699 and NIH Counter Act Award U54 NS127758 (B.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway

  • Jurado-Aguilar, Javier
  • Barroso, Emma
  • Bernard, Maribel
  • Zhang, Meijian
  • Peyman, Mona
  • Rada, Patricia
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
[Introduction]: The levels of the cellular energy sensor AMP-activated protein kinase (AMPK) have been reported to be decreased via unknown mechanisms in the liver of mice deficient in growth differentiation factor 15 (GDF15). This stress response cytokine regulates energy metabolism mainly by reducing food intake through its hindbrain receptor GFRAL., [Objective]: To examine how GDF15 regulates AMPK., [Methods]: Wild-type and Gdf15−/− mice, mouse primary hepatocytes and the human hepatic cell line Huh-7 were used., [Results]: Gdf15−/− mice showed glucose intolerance, reduced hepatic phosphorylated AMPK levels, increased levels of phosphorylated mothers against decapentaplegic homolog 3 (SMAD3; a mediator of the fibrotic response), elevated serum levels of transforming growth factor (TGF)-β1, as well as upregulated gluconeogenesis and fibrosis. In line with these observations, recombinant (r)GDF15 promoted AMPK activation and reduced the levels of phosphorylated SMAD3 and the markers of gluconeogenesis and fibrosis in the liver of mice and in mouse primary hepatocytes, suggesting that these effects may be independent of GFRAL. Pharmacological inhibition of SMAD3 phosphorylation in Gdf15−/− mice prevented glucose intolerance, the deactivation of AMPK and the increase in the levels of proteins involved in gluconeogenesis and fibrosis, suggesting that overactivation of the TGF-β1/SMAD3 pathway is responsible for the metabolic alterations in Gdf15−/− mice., [Conclusions]: Overall, these findings indicate that GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis by lowering the activity of the TGF-β1/SMAD3 pathway., This study was partly supported by the grants PID2021-122116OB-I00 (M.V.-C.) and PID2021-122766OB-I00 (A.M.V.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells

  • Zhang, Meijian
  • Barroso, Emma
  • Peña, Lucía
  • Rada, Patricia
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
The role of peroxisome proliferator-activated receptor (PPAR)β/δ in hepatic fibrosis remains a subject of debate. Here, we examined the effects of a PPARβ/δ agonist on the pathogenesis of liver fibrosis and the activation of hepatic stellate cells (HSCs), the main effector cells in liver fibrosis, in response to the pro-fibrotic stimulus transforming growth factor-β (TGF-β). The PPARβ/δ agonist GW501516 completely prevented glucose intolerance and peripheral insulin resistance, blocked the accumulation of collagen in the liver, and attenuated the expression of inflammatory and fibrogenic genes in mice fed a choline-deficient high-fat diet (CD-HFD). The antifibrogenic effect of GW501516 observed in the livers CD-HFD-fed mice could occur through an action on HSCs since primary HSCs isolated from Ppard-/- mice showed increased mRNA levels of the profibrotic gene Col1a1. Moreover, PPARβ/δ activation abrogated TGF-β1-mediated cell migration (an indicator of cell activation) in LX-2 cells (immortalized activated human HSCs). Likewise, GW501516 attenuated the phosphorylation of the main downstream intracellular protein target of TGF-β1, suppressor of mothers against decapentaplegic (SMAD)3, as well as the levels of the SMAD3 co-activator p300 via the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of extracellular signal-regulated kinase-1/2 (ERK1/2) in LX-2 cells. Overall, these findings uncover a new mechanism by which the activation of AMPK by a PPARβ/δ agonist reduces TGF-β1-mediated activation of HSCs and fibrosis via the reduction of both SMAD3 phosphorylation and p300 levels., This study was partly supported by the grants PID2021-122116OB-I00 (X.P. and M.V-C.) and PID2021-122766OB-I00 (A.M.V.) funded by MICIU/AEI/10.13039/501100011033 and by “ERDF, A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. We also acknowledge support from the CERCA Programme/Generalitat de Catalunya. E.B is a Serra Hunter fellow. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GADD45A suppression contributes to cardiac remodeling by promoting inflammation, fibrosis and hypertrophy

  • Rostami, Adel
  • Palomer, Xavier
  • Pizarro-Delgado, Javier
  • Peña, Lucía
  • Zamora, Mònica
  • Montori-Grau, Marta
  • Barroso, Emma
  • Valenzuela-Alcaraz, Brenda
  • Crispi, Fàtima
  • Salvador Sánchez, Jesús María
  • García, Raquel
  • Hurlé, María A
  • Nistal, Francisco
  • Vázquez-Carrera, Manuel
Supplementary Information The online version containssupplementary material available at https://doi.org/10.1007/s00018-025-05704-x, The growth arrest and DNA damage inducible 45A (GADD45A) is a multifaceted protein associated with stress signaling and cellular injury. Aside its well-established tumor suppressor activity, recent studies point to additional roles for GADD45A, including the regulation of catabolic and anabolic pathways, or the prevention of inflammation, fibrosis, and oxidative stress in some tissues and organs. However, little is known about its function in cardiac disease. In this study, we aimed to evaluate the role of GADD45A in the heart by using mice with constitutive and systemic deletion of Gadd45a, and cardiac cells of human origin. Gadd45a suppression in knockout mice triggered cardiac fibrosis, inflammation, and apoptosis, and these changes correlated with an hyperactivation of the pro-inflammatory and pro-fibrotic transcription factors activator protein-1 (AP-1), nuclear factor-κB (NF-κB), and signal transducer and activator of transcription 3 (STAT3). Deletion of Gadd45a also resulted in substantial cardiac hypertrophy, which negatively impacted cardiac morphology and function in knockout mice. Consistent with this, GADD45A overexpression in human AC16 cardiomyocytes partially prevented the inflammatory and fibrotic responses induced by tumor necrosis factor-α (TNF-α). Overall, data presented in this study highlight an important role for GADD45A in the heart, since it may prevent inflammation, fibrosis, and apoptosis, and, by this means, preserve cardiac function and performance. Since fibrosis and inflammation are crucial in the progression of cardiac hypertrophy and subsequent heart failure, these results suggest that promoting the activity of this protein might be a promising therapeutic strategy to slow down the progression of these deleterious diseases., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was partly supported by the grants PID2021-122116OB-I00 (M.V.-C. and X.P.), funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and “ERDF, A Way of Making Europe”, and the “Fundació La Marató de TV3” to M.V-C. CIBER in Diabetes and Associated Metabolic Diseases (CIBERDEM), CIBER of Rare Diseases (CIBERER), and CIBER in Cardiovascular Diseases (CIBERCV) are Carlos III Health Institute projects. Support was also received from the CERCA Programme/Generalitat, and from grants PI21/00084 (Carlos III Health Institute) and INNVAL21/24 (IDIVAL) to F.N., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SIRT1 regulates hepatic vldlr levels

  • Peyman, Mona
  • Babin-Ebell, Anna
  • Rodríguez Rodríguez, Rosalía
  • Rigon, Matilde
  • Aguilar-Recarte, David
  • Villarroya, Joan
  • Planavila, Anna
  • Villarroya, Francesc
  • Palomer, Xavier
  • Barroso, Emma
  • Vázquez-Carrera, Manuel
This study was partly supported by the grant PID2021-122116OB-I00 (M.V.-C.) funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by “ERDF, A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya., Background: Endoplasmic reticulum (ER) stress-mediated increases in the hepatic levels of the very low-density lipoprotein (VLDL) receptor (VLDLR) promote hepatic steatosis by increasing the delivery of triglyceride-rich lipoproteins to the liver. Here, we examined whether the NAD(+)-dependent deacetylase sirtuin 1 (SIRT1) regulates hepatic lipid accumulation by modulating VLDLR levels and the subsequent uptake of triglyceride-rich lipoproteins. Methods: Rats fed with fructose in drinking water, Sirt1−/− mice, mice treated with the ER stressor tunicamycin with or without a SIRT1 activator, and human Huh-7 hepatoma cells transfected with siRNA or exposed to tunicamycin or different inhibitors were used. Results: Hepatic SIRT1 protein levels were reduced, while those of VLDLR were upregulated in the rat model of metabolic dysfunction-associated steatotic liver disease (MASLD) induced by fructose-drinking water. Moreover, Sirt1−/− mice displayed increased hepatic VLDLR levels that were not associated with ER stress, but were accompanied by an increased expression of hypoxia-inducible factor 1α (HIF-1α)-target genes. The pharmacological inhibition or gene knockdown of SIRT1 upregulated VLDLR protein levels in the human Huh-7 hepatoma cell line, with this increase abolished by the pharmacological inhibition of HIF-1α. Finally, SIRT1 activation prevented the increase in hepatic VLDLR protein levels in mice treated with the ER stressor tunicamycin. Conclusions: Overall, these findings suggest that SIRT1 attenuates fatty liver development by modulating hepatic VLDLR levels., info:eu-repo/semantics/publishedVersion
Docta Complutense
Publicación Artículo científico (JournalArticle)

Relocation of recent shallow seismic activity in the alboran sea (western mediterranean sea): The 2021–2024, 2016, and 2004 seismic series

  • Lozano, Lucía
  • Buforn Peiró, Vicenta María Elisa
  • Cantavella, Juan Vicente
  • Lopez-Sanchez, Carolina
  • Manzanedo, Maria Victoria
  • Barco, Jaime
  • Anton, Resurreccion
  • Cabieces, Roberto
  • Mattesini, Maurizio
The Alboran Sea is a complex tectonic region and one of the most seismically active areas in the westernmost Mediterranean Sea. Its southern sector has been the scene of three significant earthquakes in the past 30 yr, the 1994 M 5.9 and 2004 M 6.3 Al Hoceima and the 2016 Mw 6.4 Alboran events. In this study, we perform a high-precision relocation of a selected subset of moderate-magnitude earthquakes of the three main seismic series that have occurred in this region in this century, the 2021-2024, 2016, and 2004 series, using all the available seismic data. We apply a two-step shared relocation procedure, first, a nonlinear probabilistic algorithm with a 3D velocity model for the Alboran-Betic-Rif system, and second, a double-difference relative method. Our results for the 2021-2024 and 2016 series show clustered epicenters along the nearby active fault systems in the area. The 2016 series displays an excellent spatial correlation with the Al-Idrisi fault and may be linked to it, whereas the 2021-2024 series could be associated to an unmapped structure to the east of Al-Idrisi, more fractured and of smaller dimensions, as inferred from its spatial-temporal magnitude distribution. Our solutions for the 2004 series confirm two clear and perpendicular epicentral alignments, which may be related to the Trougout fault. The overall depth distribution reveals shallow hypocenters mainly constrained in a seismogenic layer up to 15-20 km. Our results display a remarkable hypocentral clustering compared with the Instituto Geogr & aacute;fico Nacional (IGN) earthquake catalog solutions and an improvement in the accuracy and precision of earthquake locations, with mean horizontal and vertical uncertainties lower than similar to 5 km, giving better constrained hypocenters over the IGN catalog. Our findings highlight the effectiveness of this methodology, especially in the case of offshore seismicity with poor azimuthal coverage, and may improve seismic hazard studies in the region.